Cevec Pharmaceuticals CEO stresses challenges in producing AAV vectors
It will be a real challenge to produce sufficient quantities of gene therapy products, in particular when it comes to adeno-associated virus (AAV) vectors, according to Nicole Faust, CEO and chief science officer of Cevec Pharmaceuticals. Faust talked to ScienceBoard.net at the Cell & Gene Meeting on the Med last week in Barcelona, Spain. Read More
Investment continues in cell and gene sector, despite disruptions
Investment in the cell and gene therapy sector remains robust, despite the disruptions over the last several years due to the COVID-19 pandemic. That's one of the take-home messages from this week's Cell & Gene Meeting on the Mediterranean, according to ScienceBoard Vice President of Digital Media Sales Walt Schoenborn and reporter Melisande Rouger, who were on site in Barcelona, Spain. Read More
Regional government steps in to boost gene therapy manufacturing in Spain
BARCELONA, SPAIN -- Early cooperation between the government of the Basque region in northern Spain and companies can help boost manufacturing of gene therapies, according to Gotzone Sagardui, health minister for the Basque Country. ScienceBoard.net spoke with Sagardui during the Cell & Gene Meeting on the Med earlier this week. Read More
Context Therapeutics highlights data on ONA-XR and CLDN6 at AACR 2022
Context Therapeutics released preclinical data from two of its clinical programs to treat women’s cancers at the American Association for Cancer Research (AACR) annual meeting. ScienceBoard spoke with Context Therapeutics CEO and co-founder Martin Lehr at the show. Read More
NKILT moves from stealth mode to active fundraising
ScienceBoard.net recently caught up with NKILT Therapeutics leaders Raphael Ognar and Henri Bayle at the 2022 American Association for Cancer Research Annual Meeting in New Orleans. Read More
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter